Stock 1783 MAXIGEN BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Maxigen Biotech Inc.

Equities

1783

TW0001783009

Personal Products

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
42.9 TWD -0.23% Intraday chart for Maxigen Biotech Inc. +1.54% -11.36%
Mar. 21 Maxigen Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,608 1,754 1,591 3,996 4,036 4,304
Enterprise Value (EV) 1 1,439 1,563 1,393 3,479 3,236 3,873
P/E ratio 29.9 x 30.7 x 25.2 x 43.2 x 29.1 x 26.2 x
Yield 2.94% 3.09% 3.19% - 1.05% -
Capitalization / Revenue 3.76 x 3.88 x 3.48 x 7.81 x 6.68 x 6.92 x
EV / Revenue 3.37 x 3.46 x 3.04 x 6.79 x 5.35 x 6.23 x
EV / EBITDA 19.9 x 16.4 x 15.3 x 29.1 x 20.7 x 21.9 x
EV / FCF 17.8 x 22.2 x 37.5 x 48.7 x 15.4 x 42.4 x
FCF Yield 5.61% 4.51% 2.67% 2.06% 6.48% 2.36%
Price to Book 1.92 x 2.06 x 1.85 x 3.5 x 3.11 x 3.16 x
Nbr of stocks (in thousands) 80,232 80,232 80,232 88,934 88,934 88,934
Reference price 2 20.04 21.86 19.83 44.94 45.38 48.40
Announcement Date 3/27/19 3/31/20 3/25/21 3/23/22 3/23/23 3/21/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 427.7 452.2 457.7 512 604.4 622.1
EBITDA 1 72.42 95.14 91.12 119.7 156.7 177.1
EBIT 1 46.19 65.62 61.01 89.95 128.6 149.8
Operating Margin 10.8% 14.51% 13.33% 17.57% 21.28% 24.09%
Earnings before Tax (EBT) 1 57.31 72.8 76.74 97.47 165.8 193.1
Net income 1 57.06 60.11 63.31 87.67 139.4 165.8
Net margin 13.34% 13.29% 13.83% 17.12% 23.06% 26.66%
EPS 2 0.6714 0.7128 0.7879 1.039 1.562 1.850
Free Cash Flow 1 80.73 70.46 37.15 71.5 209.7 91.4
FCF margin 18.88% 15.58% 8.12% 13.97% 34.69% 14.69%
FCF Conversion (EBITDA) 111.49% 74.05% 40.77% 59.72% 133.81% 51.61%
FCF Conversion (Net income) 141.5% 117.21% 58.68% 81.56% 150.42% 55.12%
Dividend per Share 2 0.5892 0.6753 0.6320 - 0.4762 -
Announcement Date 3/27/19 3/31/20 3/25/21 3/23/22 3/23/23 3/21/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 169 191 198 518 800 431
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 80.7 70.5 37.2 71.5 210 91.4
ROE (net income / shareholders' equity) 6.96% 7.1% 7.4% 8.76% 11.4% 12.5%
ROA (Net income/ Total Assets) 2.58% 3.53% 3.56% 5.06% 5.93% 6.37%
Assets 1 2,213 1,701 1,778 1,732 2,352 2,603
Book Value Per Share 2 10.40 10.60 10.70 12.80 14.60 15.30
Cash Flow per Share 2 2.300 3.340 2.610 5.770 8.890 4.850
Capex 1 19.6 23.1 10.7 14.3 14.3 22.4
Capex / Sales 4.57% 5.1% 2.35% 2.78% 2.36% 3.61%
Announcement Date 3/27/19 3/31/20 3/25/21 3/23/22 3/23/23 3/21/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Cosmetics & Perfumes

1st Jan change Capi.
MAXIGEN BIOTECH INC. Stock Maxigen Biotech Inc.
-11.36% 118M
L'ORÉAL Stock L'Oréal
-2.16% 254B
GALDERMA GROUP AG Stock Galderma Group AG
0.00% 18.26B
SHISEIDO COMPANY, LIMITED Stock Shiseido Company, Limited
+0.38% 11.16B
COTY INC. Stock Coty Inc.
-6.60% 10.38B
AMOREPACIFIC CORPORATION Stock Amorepacific Corporation
+16.34% 7.63B
PROYA COSMETICS CO.,LTD. Stock Proya Cosmetics Co.,Ltd.
+10.15% 5.97B
NATURA &CO HOLDING S.A. Stock Natura &Co Holding S.A.
+1.12% 4.65B
INTER PARFUMS, INC. Stock Inter Parfums, Inc.
-17.29% 3.81B
INTERPARFUMS Stock Interparfums
-5.56% 3.54B
Cosmetics & Perfumes
  1. Stock Market
  2. Equities
  3. 1783 Stock
  4. Financials Maxigen Biotech Inc.